Abstract: Disclosed are new compounds for treating, preventing or inhibiting a parasitic disease, preferably toxoplasmosis in a subject, the method for preparing thereof.

Abstract: Compounds of formula wherein n is 0, 1 or 2; X is and Ar is a benzyl substituted at the meta position by a C1 to C8 alkoxy group, or a pharmaceutically acceptable salt thereof, for treating, preventing or inhibiting a parasitic disease, such as toxoplasmosis, in a subject are provided. Methods for preparing the compounds are also presented.

Abstract: Disclosed herein are methods of controlling polymer properties in polymerization processes that use a chromium-based catalyst. An embodiment discloses a method of producing a polyolefin comprising: contacting a reaction mixture and a reduced chromium oxide catalyst in a gas-phase reactor to produce the polyolefin, wherein the reaction mixture comprises a monomer and a co-monomer; and changing a reaction temperature in the gas-phase reactor by about 1° C. or more whereby a gas molar ratio of the co-monomer to the monomer is changed by about 2% or more and a co-monomer content of the polyolefin at substantially constant density is changed by about 2% or more. Additional methods and compositions are also provided.

Abstract: Disclosed are new compounds for treating, preventing or inhibiting a parasitic disease, preferably toxoplasmosis in a subject, the method for preparing thereof.

Abstract: The present invention is directed to salts of 3-(3-amino-2-(R)-hydroxy-propyl)-1-(4-fluoro-phenyl)-8-(8-methyl-naphthalen-1-ylmethyl)-1,3,8-triaza-spiro[4.5]decan-4-one, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by NOP, for example depression, anxiety, alcohol abuse, etc. The present invention is further directed to process(es) for the preparation of 3-(3-amino-2-(R)-hydroxy-propyl)-1-(4-fluoro-phenyl)-8-(8-methyl-naphthalen-1-ylmethyl)-1,3,8-triaza-spiro[4.5]decan-4-one and its corresponding salts.

Abstract: The present invention relates to the fumarate salt of (alpha S, beta R)-6-bromo-alpha-[2-(dimethylamino)ethyl]-2-methoxy-alpha-1-naphthalenyl-beta-phenyl-3-quinolineethanol, pharmaceutical compositions comprising as active ingredient said salt and to processes for their preparation.

Abstract: A water vehicle moving on or in a liquid and including a flotation element (1) that is connected by a connection member (6) to a carrier (3), the water vehicle being characterized in that the connection member (6) is shaped so as to enable the carrier (3) to assume at least two positions, namely:—a raised position where the longitudinal axis of the carrier (3) and those of the flotation element (1) substantially extend into the same horizontal plane, the carrier (3) then being on the surface and capable of making up a central shell; and—a lowered position where the carrier (3) extends under the plane including the longitudinal axis of each of the flotation element (1), the carrier (3) then being submerged.

Abstract: The present invention relates to the fumarate salt of (alpha S, beta R)-6-bromo-alpha-[2-(dimethylamino)ethyl]-2-methoxy-alpha-1 -naphthalenyl-beta-phenyl-3-quinolineethanol, pharmaceutical compositions comprising as active ingredient said salt and to processes for their preparation.

Abstract: The present invention is directed to salts of 3-(3-amino-2-(R)-hydroxy-propyl)-1-(4-fluoro-phenyl)-8-(8-methyl-naphthalen-1-ylmethyl)-1,3,8-triaza-spiro[4.5]decan-4-one, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by NOP, for example depression, anxiety, alcohol abuse, etc. The present invention is further directed to process(es) for the preparation of 3-(3-amino-2-(R)-hydroxy-propyl)-1-(4-fluoro-phenyl)-8-(8-methyl-naphthalen-1-ylmethyl)-1,3,8-triaza-spiro[4.5]decan-4-one and its corresponding salts.